Jump to content

Avax initiates lung cancer vaccine trial

Recommended Posts

http://www.pharmaceutical-business-revi ... 0E922969DF

19th January 2006

By Staff Writer

Avax Technologies is commencing enrollment in its phase I/II study in patients with non-small cell lung cancer.

AdvertisementThe vaccine is composed of tumor cells obtained from each patient's tumor that are modified with dinitrophenyl. Endpoints of the study include safety and a measure of each patient's immune response to their cancer after vaccination using a delayed-type hypersensitivity test.

"Based upon previous observations of regression of melanoma lung metastases after administration of M-Vax, our AC Vaccine Therapeutic for the treatment of melanoma plus initial results obtained in our animal model, we feel there is a strong rationale for testing the vaccine in lung cancer," Dr David Berd, chief medical officer of Avax.

The study will include patients whose lung cancers are completely resectable. They will be assigned to one of three vaccine doses, and the dose is measured by the number of cancer cells. Each dosage arm will include a maximum of 14 patients.

The study subjects will receive vaccine treatment immediately after surgery and prior to any other adjuvant treatment. Based upon anticipated enrollment the company expects to obtain initial immunological data from the study in the second quarter of 2006.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.